Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), ...

Fox’s departure has left Malik Monk as the team’s de facto point guard despite originally joining the team in 2022 to provide ...

So, the natural question for Monte Rosa Therapeutics (NASDAQ:GLUE) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash ...

So, the natural question for Monte Rosa Therapeutics (NASDAQ:GLUE) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Last month, the pharma put forth $1 billion in upfront payments and up to $1.9 billion in milestone commitments to license PTC Therapeutics’ Huntington’s disease drug. Just weeks earlier, Novartis ...

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company with a market capitalization of $568 million and an impressive 203% return over the past year, has ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...